# Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

> **NCT01020968** · PHASE2 · COMPLETED · sponsor: **Vericel Corporation** · enrollment: 22 (actual)

## Conditions studied

- Dilated Cardiomyopathy

## Interventions

- **BIOLOGICAL:** Ixmyelocel-T
- **OTHER:** Vehicle Control

## Key facts

- **NCT ID:** NCT01020968
- **Lead sponsor:** Vericel Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-01-11
- **Final completion:** 2013-12-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020968, "Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01020968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*